Ocular Therapeutix Inc (OCUL) - Total Liabilities
Based on the latest financial reports, Ocular Therapeutix Inc (OCUL) has total liabilities worth $153.75 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Ocular Therapeutix Inc generate cash to assess how effectively this company generates cash.
Ocular Therapeutix Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Ocular Therapeutix Inc's total liabilities have evolved over time, based on quarterly financial data. Check OCUL cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Ocular Therapeutix Inc Competitors by Total Liabilities
The table below lists competitors of Ocular Therapeutix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BBMG Corp Class A
SHG:601992
|
China | CN¥208.39 Billion |
|
Nava Bharat Ventures Limited
NSE:NAVA
|
India | Rs25.14 Billion |
|
AMP Limited
F:AMP
|
Germany | €30.47 Billion |
|
H&R Real Estate Investment Trust
TO:HR-UN
|
Canada | CA$4.97 Billion |
|
Alliance Financial Group Bhd
KLSE:2488
|
Malaysia | RM77.88 Billion |
|
Jinfu Technology Co Ltd
SHE:003018
|
China | CN¥358.76 Million |
|
Goodyear Tire & Rubber Co
NASDAQ:GT
|
USA | $14.80 Billion |
|
Triumph Group Inc
NYSE:TGI
|
USA | $1.70 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Ocular Therapeutix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Ocular Therapeutix Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ocular Therapeutix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ocular Therapeutix Inc (2012–2025)
The table below shows the annual total liabilities of Ocular Therapeutix Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $153.75 Million | +7.82% |
| 2024-12-31 | $142.59 Million | -11.40% |
| 2023-12-31 | $160.93 Million | +41.28% |
| 2022-12-31 | $113.91 Million | -2.55% |
| 2021-12-31 | $116.89 Million | -37.08% |
| 2020-12-31 | $185.77 Million | +125.53% |
| 2019-12-31 | $82.37 Million | +121.62% |
| 2018-12-31 | $37.17 Million | +26.92% |
| 2017-12-31 | $29.28 Million | +27.70% |
| 2016-12-31 | $22.93 Million | +10.68% |
| 2015-12-31 | $20.72 Million | +6.26% |
| 2014-12-31 | $19.50 Million | -75.20% |
| 2013-12-31 | $78.62 Million | +9.35% |
| 2012-12-31 | $71.90 Million | -- |
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more